Payment overview · 2025
General Payments
$1,899.12
115 reported records · 21 companies
Healthcare provider profile · identity verified
John Patrick Mullally, MD
Allopathic & Osteopathic Physicians|Family Medicine · PORT HURON, MI · NPI 1033105630
Verified facts
What the public records show
CMS Open Payments records show John Patrick Mullally, MD received $1,899.12 in general payments during 2025 across 115 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Farxiga, Kerendia, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 340 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 232 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $331.87 | 17.5% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $240.53 | 12.7% | 18 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $238.49 | 12.6% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $155.70 | 8.2% | 16 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $154.76 | 8.2% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $139.65 | 7.3% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $138.90 | 7.3% | 11 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $58.82 | 3.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $55.19 | 2.9% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $50.25 | 2.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $49.27 | 2.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $45.81 | 2.4% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $40.61 | 2.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $38.20 | 2.0% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.45 | 1.7% | 2 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $30.41 | 1.6% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $29.78 | 1.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.23 | 1.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.25 | 0.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.29 | 0.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.66 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,899.12 | 115 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $315.54 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $254.75 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $238.49 | 14 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $238.42 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $156.15 | 12 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $154.76 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $126.77 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $118.98 | 13 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $113.51 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $109.69 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $105.81 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $68.93 | 8 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $58.82 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $50.25 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $49.27 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $45.81 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $40.61 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.15 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $31.45 | 2 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $30.41 | 2 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $29.78 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.23 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.75 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $12.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 38 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 139 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 210 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 128 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 340 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
72 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
38 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
139 | 41 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
81 | 23 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
340 | 70 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
50 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
210 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
232 | 40 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
128 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1075 | 137 |
| Montelukast Sodium | Montelukast Sodium | 671 | 230 |
| Omeprazole | Omeprazole | 605 | 191 |
| Atorvastatin Calcium | Atorvastatin Calcium | 557 | 149 |
| Alprazolam | Alprazolam | 491 | 78 |
| Furosemide | Furosemide | 451 | 125 |
| Levothyroxine Sodium | Levothyroxine Sodium | 409 | 104 |
| Gabapentin | Gabapentin | 399 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 368 | 118 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 340 | 70 |
| Potassium Chloride | Potassium Chloride | 297 | 74 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 276 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 256 | 87 |
| Eliquis | Apixaban | 254 | 49 |
| Losartan Potassium | Losartan Potassium | 249 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 246 | 83 |
| Metformin Hcl | Metformin Hcl | 244 | 64 |
| Metoprolol Tartrate | Metoprolol Tartrate | 237 | 62 |
| Methylprednisolone | Methylprednisolone | 232 | 149 |
| Trulicity | Dulaglutide | 232 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 217 | 64 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 214 | 31 |
| Mounjaro | Tirzepatide | 210 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 186 | 57 |
| Ibuprofen | Ibuprofen | 175 | 46 |
| Spironolactone | Spironolactone | 166 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 160 | 43 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 157 | 60 |
| Clonazepam | Clonazepam | 155 | 19 |
| Tramadol Hcl | Tramadol Hcl | 154 | 38 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 149 | 47 |
| Lisinopril | Lisinopril | 146 | 45 |
| Pregabalin | Pregabalin | 141 | 15 |
| Midodrine Hcl | Midodrine Hcl | 140 | 38 |
| Farxiga | Dapagliflozin Propanediol | 139 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 132 | 20 |
| Ozempic | Semaglutide | 128 | 22 |
| Prednisone | Prednisone | 127 | 78 |
| Spiriva Respimat | Tiotropium Bromide | 127 | 38 |
| Atenolol | Atenolol | 126 | 35 |
| Ropinirole Hcl | Ropinirole Hcl | 125 | 20 |
| Simvastatin | Simvastatin | 125 | 34 |
| Carvedilol | Carvedilol | 119 | 31 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 116 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 114 | 24 |
| Azithromycin | Azithromycin | 113 | 69 |
| Sertraline Hcl | Sertraline Hcl | 113 | 22 |
| Bumetanide | Bumetanide | 110 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 108 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 38 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 102 | 61 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 101 | 26 |
| Meloxicam | Meloxicam | 98 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 93 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 86 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 85 | 71 |
| Allopurinol | Allopurinol | 84 | 25 |
| Levofloxacin | Levofloxacin | 83 | 51 |
| Ondansetron Hcl | Ondansetron Hcl | 82 | 23 |
| Symbicort | Budesonide/Formoterol Fumarate | 81 | 23 |
| Buspirone Hcl | Buspirone Hcl | 76 | 22 |
| Trazodone Hcl | Trazodone Hcl | 74 | 23 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 73 | 56 |
| Myrbetriq | Mirabegron | 72 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 23 |
| Cephalexin | Cephalexin | 70 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 19 |
| Propranolol Hcl | Propranolol Hcl | 70 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 14 |
| Lorazepam | Lorazepam | 67 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 16 |
| Ezetimibe | Ezetimibe | 64 | 19 |
| Memantine Hcl | Memantine Hcl | 64 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 64 | 26 |
| Cholestyramine | Cholestyramine (With Sugar) | 62 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 20 |
| Lactulose | Lactulose | 59 | 28 |
| Cefdinir | Cefdinir | 58 | 47 |
| Dicyclomine Hcl | Dicyclomine Hcl | 57 | 13 |
| Terbinafine Hcl | Terbinafine Hcl | 56 | 23 |
| Amoxicillin | Amoxicillin | 55 | 34 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 39 |
| Diazepam | Diazepam | 54 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 53 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 53 | suppressed |
| Dexamethasone | Dexamethasone | 52 | 37 |
| Methylphenidate Hcl | Methylphenidate Hcl | 52 | suppressed |
| Glimepiride | Glimepiride | 51 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 17 |
| Famotidine | Famotidine | 50 | 20 |
| Jardiance | Empagliflozin | 50 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 48 | 27 |
| Testosterone Cypionate | Testosterone Cypionate | 46 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 44 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 13 |
| Lamotrigine | Lamotrigine | 43 | suppressed |
| Temazepam | Temazepam | 43 | suppressed |
| Fluconazole | Fluconazole | 42 | 23 |
| Novolog Flexpen | Insulin Aspart | 42 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 16 |
| Topiramate | Topiramate | 42 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 40 | suppressed |
| Lidocaine | Lidocaine | 40 | 13 |
| Donepezil Hcl | Donepezil Hcl | 39 | 13 |
| Airsupra | Albuterol Sulfate/Budesonide | 38 | 21 |
| Bupropion Xl | Bupropion Hcl | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 15 |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 24 |
| Nystatin | Nystatin | 36 | 24 |
| Incruse Ellipta | Umeclidinium Bromide | 35 | suppressed |
| Sucralfate | Sucralfate | 35 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 34 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Levetiracetam | Levetiracetam | 33 | 11 |
| Lovastatin | Lovastatin | 33 | 11 |
| Colchicine | Colchicine | 32 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 30 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 30 | 19 |
| Kerendia | Finerenone | 30 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 19 |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | 11 |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Carisoprodol | Carisoprodol | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 15 |
| Glycopyrrolate | Glycopyrrolate | 24 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Budesonide | Budesonide | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Metronidazole | Metronidazole | 23 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Lubiprostone | Lubiprostone | 22 | suppressed |
| Novolog | Insulin Aspart | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 21 | 14 |
| Celecoxib | Celecoxib | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | 14 |
| Rexulti | Brexpiprazole | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Dulera | Mometasone/Formoterol | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Haloperidol | Haloperidol | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Repaglinide | Repaglinide | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Dronabinol | Dronabinol | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Olanzapine | Olanzapine | 16 | suppressed |
| Relpax | Eletriptan Hydrobromide | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 14 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Zafirlukast | Zafirlukast | 13 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 11 | suppressed |
| Dasetta | Norethindrone-Ethin. Estradiol | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,899.12 · 115 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JATENZO, KISUNLA, Kerendia, Korlym, MOUNJARO, OTEZLA, Ozempic, Prolastin-C Liquid, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, WAKIX, Wegovy, XIFAXAN, YUPELRI, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error